In vitro analysis of cell populations involved in Hodgkin's disease lesions and in the characteristic T cell immunodeficiency

1988 ◽  
Vol 6 (3) ◽  
pp. 247-255 ◽  
Author(s):  
Richard J. Ford ◽  
Chitra Rajaraman ◽  
Ming Lu ◽  
Mark Blick
Keyword(s):  
T Cell ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Cell Populations ◽  
T Cell Immunodeficiency ◽  
Vitro Analysis ◽  
In Vitro Analysis

scholarly journals Generation of immune cell containing adipose organoids for in vitro analysis of immune metabolism

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Jacqueline Taylor ◽  
Julia Sellin ◽  
Lars Kuerschner ◽  
Lennart Krähl ◽  
Yasmin Majlesain ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Adipocyte Differentiation ◽  
Immune Cell ◽  
Stromal Vascular Fraction ◽  
Cell Populations ◽  
Endocrine Organ ◽  
Vitro Analysis ◽  
In Vitro Analysis ◽  
Better Than

AbstractAdipose tissue is an organized endocrine organ with important metabolic and immunological functions and immune cell-adipocyte crosstalk is known to drive various disease pathologies. Suitable 3D adipose tissue organoid models often lack resident immune cell populations and therefore require the addition of immune cells isolated from other organs. We have created the first 3D adipose tissue organoid model which could contain and maintain resident immune cell populations of the stromal vascular fraction (SVF) and proved to be effective in studying adipose tissue biology in a convenient manner. Macrophage and mast cell populations were successfully confirmed within our organoid model and were maintained in culture without the addition of growth factors. We demonstrated the suitability of our model for monitoring the lipidome during adipocyte differentiation in vitro and confirmed that this model reflects the physiological lipidome better than standard 2D cultures. In addition, we applied mass spectrometry-based lipidomics to track lipidomic changes in the lipidome upon dietary and immunomodulatory interventions. We conclude that this model represents a valuable tool for immune-metabolic research.

scholarly journals In vitro analysis of antigen induced T cell-monocyte conjugates by imaging flow cytometry

2018 ◽  
Vol 460 ◽  
pp. 93-100
Author(s):  
Meseret Habtamu ◽  
Markos Abebe ◽  
Abraham Aseffa ◽  
Anne Margarita Dyrhol-Riise ◽  
Anne Spurkland ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
T Cell ◽  
Imaging Flow Cytometry ◽  
Vitro Analysis ◽  
In Vitro Analysis

scholarly journals In vitro analysis of cytotoxic T cell recruitment mediated by the DC-derived chemokine CCL17

2010 ◽  
Author(s):  
Thomas Quast ◽  
Verena Semmling ◽  
Christian Kurts ◽  
Irmgard Förster ◽  
Waldemar Kolanus
Keyword(s):  
T Cell ◽  
Cytotoxic T Cell ◽  
Cell Recruitment ◽  
Vitro Analysis ◽  
In Vitro Analysis

scholarly journals Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model

Blood ◽  
1996 ◽  
Vol 87 (7) ◽  
pp. 2930-2937 ◽  
Author(s):  
C Renner ◽  
S Bauer ◽  
U Sahin ◽  
W Jung ◽  
R van Lier ◽  
...  
Keyword(s):  
T Cells ◽  
Monoclonal Antibodies ◽  
T Cell ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Scid Mice ◽  
T Cell Subsets ◽  
Human T Cell ◽  
Human T Cells

Cure of a single established human Hodgkin's tumor growing subcutaneously in severe combined immunodeficient (SCID) mice can be achieved with a complex protocol using two bispecific monoclonal antibodies (Bi-MoAb) directed against the Hodgkin's associated CD30 antigen and the T-cell triggering molecules CD3 and CD28, respectively, together with human T cells prestimulated in vitro with Bi-MoAbs in the presence of CD30+ cells. To adapt this model to the clinical situation, disseminated tumors were established in SCID mice by intravenous injection of 2 x 10(7) cells of the Hodgkin's derived cell line L540CY. Treatment of SCID mice bearing disseminated CD30+ Hodgkin's tumors with the combination of CD3/CD30 and CD28/CD30 Bi-MoAbs and naive (ie, not in vitro prestimulated) human T cells resulted in the cure of all appropriately treated animals. T lymphocytes obtained from patients with advanced stage untreated Hodgkin's disease were as effective as lymphocytes from healthy controls. Treatment was effective even when delayed until 2 weeks after tumor inoculation, and application of Bi- MoAbs into SCID mice with circulating human T cells was as effective as injecting the Bi-MoAbs before the lymphocytes. Treatment results with isolated CD4+ and CD8+ human T cells suggest that both subsets are necessary for the Bi-MoAb mediated cure of xenografted human tumors in vivo. The efficacy and practicability of this preclinical immunotherapy protocol support and form the basis for the clinical evaluation of this approach in patients with Hodgkin's disease resistant to standard therapy.

scholarly journals Natural inhibitors of T-cell activation in Hodgkin's disease

Blood ◽  
1991 ◽  
Vol 78 (9) ◽  
pp. 2365-2371 ◽  
Author(s):  
M Roux ◽  
B Schraven ◽  
A Roux ◽  
H Gamm ◽  
R Mertelsmann ◽  
...  
Keyword(s):  
T Cell ◽  
T Lymphocytes ◽  
T Cell Activation ◽  
Hodgkin's Disease ◽  
Cell Activation ◽  
Cell Function ◽  
Hodgkin’S Disease ◽  
Alternative Pathway ◽  
Cellular Level

Abstract Secondary immunodeficiency is frequently observed in Hodgkin's disease (HD) and is due in part to impaired T-cell function. Using monoclonal antibodies that bind to triggering molecules of human T lymphocytes (CD3/Ti antigen receptor; CD2 E-rosette receptor) and exert functional effects on T-cell activation, we have investigated in vitro immune responses of circulating lymphocytes from patients with HD in progression (n = 9) and in remission (n = 14). In patients with progressive HD, a severe dysfunction of the alternative CD2-mediated T- cell activation pathway was detected (49.3 +/- 14.2 v 9.4 +/- 5.1 cpm x 10(-3), in controls, P less than .01; n = 9) that parallels the reduced capacity of T lymphocytes to form rosettes with sheep red blood cells. Diminished alternative pathway activation in HD is not only due to a defect at the cellular level but also due to soluble mediators in the patients' plasma. Plasma from patients in progression markedly reduces CD2 mediated activation (P less than .01). These activities interfere, at least in part, with CD2/CD58 interactions and, therefore, reduce T- lymphocyte triggering through this amplifier mechanism.

Comparative in vitro analysis of different hematopoietic cell populations from human cord blood: in search of the best option for clinically oriented ex vivo cell expansion

Transfusion ◽  
2012 ◽  
Vol 53 (3) ◽  
pp. 668-678 ◽  
Author(s):  
Patricia Flores-Guzman ◽  
Veronica Fernandez-Sanchez ◽  
Ignacio Valencia-Plata ◽  
Lourdes Arriaga-Pizano ◽  
Guadalupe Alarcon-Santos ◽  
...  
Keyword(s):  
Cord Blood ◽  
Cell Expansion ◽  
Ex Vivo ◽  
Hematopoietic Cell ◽  
Cell Populations ◽  
Human Cord Blood ◽  
Vitro Analysis ◽  
In Vitro Analysis
Sign in / Sign up

Export Citation Format

Share Document